Diversity in Clinical Trials: Why It Matters for Everyone
Diversity in clinical trials is one of the most critical factors in ensuring that new medical treatments, drugs, and devices work effectively for all people. Clinical trials are research studies conducted on humans to evaluate whether a new intervention is safe and effective. But a treatment that works well in one group may perform differently in another. Without representative participation, the data produced in clinical research cannot be generalized to the broader population. This is not a theoretical concern. It is a documented reality that shapes outcomes for millions of patients every year.
Why Diverse Representation Is a Scientific Necessity
The FDA has consistently emphasized that diversity in clinical trials is not a social initiative but a scientific requirement. Former FDA Commissioner Dr. Stephen M. Hahn pointed to COVID-19 as a clear example of why this matters. The virus affected different groups including older adults, racial and ethnic minorities, and people with underlying conditions in meaningfully different ways. Any trial working to develop a treatment or vaccine for COVID-19 that lacked diverse enrollment would produce results that could not be trusted to apply equally to all who needed protection.
This principle extends to every therapeutic area. The population enrolled in a clinical trial must reflect the population that will eventually use the treatment. If trial participants are drawn from a narrow demographic, researchers cannot be confident that the results will hold across age groups, sexes, races, ethnicities, or individuals with comorbidities.
The FDA recommends that clinical research programs actively design their studies to include participants with varied demographic characteristics such as age, sex, race, ethnicity, geographic location, income, and education level as well as non demographic factors such as organ dysfunction, disability, and rare disease status. When diversity in clinical trials is treated as a design principle rather than an afterthought, the science becomes more reliable and the treatments that emerge from it become more effective for everyone.
The Barriers That Prevent Inclusive Enrollment
Despite the recognized importance of diversity in clinical trials, underrepresentation remains a persistent challenge across the industry. Several structural barriers contribute to this gap, and understanding them is the first step toward dismantling them.
Lack of information is one of the most common obstacles. Many individuals from underrepresented communities are unaware that they may qualify to participate in a clinical trial. Others feel uncertain or intimidated because they do not understand how the process works, which makes them more vulnerable to misinformation about what trial participation actually involves. Education and outreach are essential tools for closing this gap.
Lack of trust is another significant factor. Historically, certain ethnic groups were subjected to unethical research practices. The Tuskegee Syphilis Study is one of the most widely known examples of how medical institutions violated the trust of Black Americans, conducting research without informed consent and withholding treatment for decades. These events created lasting skepticism that continues to affect willingness to participate in research today. Rebuilding that trust requires sustained, community based engagement and transparency from research organizations.
Lack of resources compounds both of the above. Financial barriers, transportation limitations, work schedule constraints, and the inability to access care create real practical obstacles for individuals who might otherwise be willing to participate. Clinical research that is only accessible to those with time, money, and proximity to major academic medical centers will always fail to represent the communities that need new treatments the most. Research sites that operate within underserved communities and offer support services to participants are better positioned to close this gap.
What Happens When Diversity Is Missing
When clinical trials lack diversity, the consequences extend far beyond the research setting. A drug that was tested predominantly in one demographic group may be approved based on data that does not reflect how it performs in others. Dosing recommendations, side effect profiles, and efficacy data may all differ across populations in ways that a homogeneous trial cannot capture.
This means that after a treatment reaches the market, patients from underrepresented groups may be using a product whose risks and benefits were never fully characterized for people like them. It is a gap that affects real health outcomes and contributes to existing disparities in the quality of care received by different communities. Diversity in clinical trials is therefore not just a matter of fairness. It is a matter of patient safety.
FOMAT’s Commitment to Inclusive Research
Addressing these barriers is at the core of what FOMAT does. Our mission is to diversify clinical trials and innovate healthcare for underrepresented populations while upholding Good Clinical Practice standards and ethics in every study we conduct. We believe that meaningful progress in medicine requires that the people most affected by disease have a seat at the table in the research designed to treat them.
FOMAT actively builds its site network in communities that have historically been excluded from clinical research. By bringing trials closer to where patients live, removing logistical barriers to participation, and engaging with communities in culturally appropriate ways, we work to ensure that diversity in clinical trials is not just a stated goal but an operational reality across every study we support.
Our investigators are experienced in working with diverse patient populations across a broad range of therapeutic areas including infectious disease, oncology, gastroenterology, nephrology, and ophthalmology. We partner with sponsors and CROs who share our commitment to building research programs that reflect the full diversity of the patients they are designed to serve.
To learn more about our active studies or our approach to inclusive clinical research, visit fomatmedical.com. For additional FDA guidance on diversity in clinical trials, visit www.fda.gov.